PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non–Small-Cell Lung Cancer
Jyoti D. Patel,Mark A. Socinski,Edward B. Garon,Craig H. Reynolds,David R. Spigel,Mark R. Olsen,Robert C. Hermann,Robert M. Jotte,Thaddeus Beck,Donald A. Richards,Susan C. Guba,Jingyi Liu,Bente Frimodt-Moller,William J. John,Coleman K. Obasaju,Eduardo J. Pennella,Philip Bonomi,Ramaswamy Govindan +17 more
Reads0
Chats0
TLDR
OS did not improve with the Pemetrexed plus bevacizumab regimen compared with the PacCBev regimen, although PFS was significantly improved with PemCBev.Abstract:
Purpose PointBreak (A Study of Pemetrexed, Carboplatin and Bevacizumab in Patients With Nonsquamous Non-Small Cell Lung Cancer) compared the efficacy and safety of pemetrexed (Pem) plus carboplatin (C) plus bevacizumab (Bev) followed by pemetrexed plus bevacizumab (PemCBev) with paclitaxel (Pac) plus carboplatin (C) plus bevacizumab (Bev) followed by bevacizumab (PacCBev) in patients with advanced nonsquamous non‐small-cell lung cancer (NSCLC).read more
Citations
More filters
Journal ArticleDOI
Smooth sailing for immunotherapy for unresectable stage III non-small cell lung cancer: the PACIFIC study.
TL;DR: The tumor microenvironment, the soil in which tumors grow in the body, has become a rich source of potential therapeutic intervention and there is now a growing appreciation of the complex contributions of each cell type to tumor growth.
Thérapies moléculaires ciblées en cancérologie pulmonaire
TL;DR: In this paper, the authors recensons les traitements which ciblent des anomalies moléculaires des cancers pulmonaires, i.e., the traitements anti-angiogéniques, les inhibiteurs des signaux de prolifération and l'immunothérapie.
Journal ArticleDOI
Cardiogenic syncope possibly related to bevacizumab-containing combination chemotherapy for advanced non-small cell lung cancer.
Haruka Chino,Yosuke Amano,Yasuhiro Yamauchi,Jun Matsuda,Norihiko Takeda,Goh Tanaka,Daiya Takai,Takahide Nagase +7 more
TL;DR: The results indicate that bevacizumab could lead to cardiotoxicity in patients with NSCLC and suggest the importance of the follow-up cardiac ultrasonography.
Journal ArticleDOI
Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapy.
J. de Castro,Jose-Luis Gonzalez-Larriba,Sergio Vázquez,B. Massuti,J. M. Sánchez-Torres,Manuel Domine,Pilar Garrido,Antonio Calles,Angel Artal,Rosa Collado,Regina Garcia,María Sereno,Margarita Majem,J. A. Macías,Oscar Juan,José Gómez-Codina,Berta Hernandez,M. Lázaro,Ana Laura Ortega,M. Cobo,Jose Manuel Trigo,Enric Carcereny,Christian D. Rolfo,Sonia Maciá,J. Muñoz,Pilar Diz,M. Méndez,F. Rosillo,Luis Paz-Ares,J. V. Cardona,Dolores Isla +30 more
TL;DR: It is shown that there is a long-term survivor group whom the administration of bevacizumab resulted in a relevant prolongation of response without new safety signals, and standardised predictive factors seem to be predictive factors of good evolution.
Journal ArticleDOI
Metastasis manners and the underlying mechanisms of ALK and ROS1 rearrangement lung cancer and current possible therapeutic strategies
TL;DR: The present review summarizes the current status of NSCLC metastasis and possible mechanisms based on available evidence, and lists possible therapeutic strategies so that an increase in control of ALK and ROS1 rearrangement of NSclC metastases by combination therapy can be translated in a increase in overall survival and prognosis.
References
More filters
Book ChapterDOI
Nonparametric Estimation from Incomplete Observations
Edward L. Kaplan,Paul Meier +1 more
TL;DR: In this article, the product-limit (PL) estimator was proposed to estimate the proportion of items in the population whose lifetimes would exceed t (in the absence of such losses), without making any assumption about the form of the function P(t).
Book ChapterDOI
Regression Models and Life-Tables
TL;DR: The analysis of censored failure times is considered in this paper, where the hazard function is taken to be a function of the explanatory variables and unknown regression coefficients multiplied by an arbitrary and unknown function of time.
Book
AJCC Cancer Staging Manual
Mahul B. Amin,Stephen B. Edge,Frederick L. Greene,David R. Byrd,Robert K. Brookland,Mary Kay Washington,Jeffrey E. Gershenwald,Carolyn C. Compton,Kenneth R. Hess,Daniel C. Sullivan,J. Milburn Jessup,James D. Brierley,Lauri E. Gaspar,Richard L. Schilsky,Charles M. Balch,David P. Winchester,Elliot A. Asare,Martin Madera,Donna M. Gress,Laura R. Meyer +19 more
TL;DR: Purposes and Principles of Cancer Staging and End-Results Reporting are explained.
Journal ArticleDOI
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Patrick Therasse,Susan G. Arbuck,Elizabeth Eisenhauer,Jantien Wanders,Richard Kaplan,Larry Rubinstein,Jaap Verweij,Martine Van Glabbeke,Allan T. van Oosterom,Michaele C. Christian,S. Gwyther +10 more
TL;DR: A model by which a combined assessment of all existing lesions, characterized by target lesions and nontarget lesions, is used to extrapolate an overall response to treatment is proposed, which is largely validated by the Response Evaluation Criteria in Solid Tumors Group and integrated into the present guidelines.
Journal ArticleDOI
Prediction of Creatinine Clearance from Serum Creatinine
Donald W. Cockcroft,M H Gault +1 more
TL;DR: A formula has been developed to predict Creatinine clearance from serum creatinine (Scr) in adult males: Ccr = (140 – age) (wt kg)/72 × Scr (mg/100ml) (15% less i).
Related Papers (5)
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
Giorgio V. Scagliotti,Purvish M. Parikh,Joachim von Pawel,Bonne Biesma,Johan Vansteenkiste,Christian Manegold,Piotr Serwatowski,Ulrich Gatzemeier,Raghunadharao Digumarti,Mauro Zukin,Jin S. Lee,Anders Mellemgaard,Keunchil Park,Shehkar Patil,Janusz Rolski,Tuncay Göksel,Filippo de Marinis,Lorinda Simms,Katherine P. Sugarman,David R. Gandara +19 more
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
Hossein Borghaei,Luis Paz-Ares,Leora Horn,D. R. Spigel,M. Steins,Neal Ready,L.Q. Chow,Everett E. Vokes,Enriqueta Felip,Esther Holgado,F. Barlesi,M. Kohlhufl,Oscar Arrieta,Marco Angelo Burgio,J. Fayette,H. Lena,Elena Poddubskaya,David E. Gerber,Scott N. Gettinger,Charles M. Rudin,Naiyer A. Rizvi,L. Crina,G. R. Blumenschein,Scott J. Antonia,C. Dorange,C. T. Harbison,F. Graf Finckenstein,Julie R. Brahmer +27 more